Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib

Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment

(2017) Ciaran Mooney et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

(2017) Shenghui He et al.   Science Translational Medicine

Dasatinib promotes the activation of quiescent hematopoietic stem cells in mice

(2016) Johanna M. Duyvestyn et al.   EXPERIMENTAL HEMATOLOGY

Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice

(2016) O. M. Dovey et al.   HAEMATOLOGICA

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

(2016) J. E. Bisi et al.   MOLECULAR CANCER THERAPEUTICS

Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice

(2016) O. M. Dovey et al.   HAEMATOLOGICA

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim

(2016) Michele Ghidini et al.   Therapeutics and Clinical Risk Management

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

(2015) L. Apetoh et al.   ANNALS OF ONCOLOGY

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice

(2015) Samuel J. Taylor et al.   EXPERIMENTAL HEMATOLOGY

Romiplostim promotes platelet recovery in a mouse model of multicycle chemotherapy-induced thrombocytopenia

(2015) Patricia L. McElroy et al.   EXPERIMENTAL HEMATOLOGY

Loss of SPARC protects hematopoietic stem cells from chemotherapy toxicity by accelerating their return to quiescence

(2014) A. Ehninger et al.   BLOOD

Inhibition of c-Kit by tyrosine kinase inhibitors

(2014) A. Galanis et al.   HAEMATOLOGICA

Clonal dynamics of native haematopoiesis

(2014) Jianlong Sun et al.   NATURE

Crenolanib is a selective type I pan-FLT3 inhibitor

(2014) C. C. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy

(2014) Alexander A Warkentin et al.   eLife

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia

(2013) E. I. Zimmerman et al.   BLOOD

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

(2013) A. Galanis et al.   BLOOD

AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model

(2013) M. Wunderlich et al.   BLOOD

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

(2013) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model

(2013) M Mallardo et al.   LEUKEMIA

A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice

(2013) A Mupo et al.   LEUKEMIA

The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions

(2013) Jasjeet Bhullar et al.   PLoS One

Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling

(2012) S. J. Taylor et al.   BLOOD

Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors

(2012) M. C. Heinrich et al.   CLINICAL CANCER RESEARCH

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation

(2011) S. Kharazi et al.   BLOOD

Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors

(2011) J. C. Montero et al.   CLINICAL CANCER RESEARCH

Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia

(2011) Emmanouil Saloustros et al.   EXPERT OPINION ON PHARMACOTHERAPY

Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice

(2011) George S Vassiliou et al.   NATURE GENETICS

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus

(2010) Q. Li et al.   BLOOD

Myeloid Leukemia Development in c-Cbl RING Finger Mutant Mice Is Dependent on FLT3 Signaling

(2010) Chozhavendan Rathinam et al.   CANCER CELL

Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development

(2010) Sergei Doulatov et al.   NATURE IMMUNOLOGY

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics

(2009) John R. Wingard et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers

(2009) Nancy L. Lewis et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer

(2008) Jianhui Yuan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Hematopoietic Stem Cells Reversibly Switch from Dormancy to Self-Renewal during Homeostasis and Repair

(2008) Anne Wilson et al.   CELL

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL